BASF
Executive Summary
Will build $ 45 mil. biotech lab and pilot plant facility in "Boston vicinity." Facility is expected to be operational by 1991 and will employ 230, including 60 scientists. R&D will focus on pharmaceuticals for treatment of cancer and immune diseases. BASF's biotech lab in W. Germany is developing TNF. The West German firm's U.S. pharmaceutical subsidiary is Knoll Pharmaceuticals.